Fundraising Fox
/Companies
Sign in

Novasenta

Pittsburgh, US · Founded 2018 · Delaware corporation · 1 known investors

Find your way into Novasenta

Sign up to see every warm intro you have to Novasenta

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Novasenta team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Novasenta was founded in 2018 by Greg M. Delgoffe, Robert Ferris, and Dario A. A. Vignali.

GMGreg M. Delgoffe
Greg M. DelgoffeFounder, Board Member
RFRobert Ferris
Robert FerrisFounder
DA
Dario A. A. VignaliFounder
MKMatthias Kleinz
Matthias KleinzNamed on SEC filing
MM
Mani MohindruNamed on SEC filing
ML
Michael Lyman, PhDCEO

Board

JC
Jeanne CunicelliBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 2 rounds · 2022–2023

▶$15MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David MooreDirector
  • Greg DelgoffeDirector
  • Jeanne CunicelliDirector
  • Mani MohindruExecutive Officer, Director
  • Matthias KleinzDirector
Offering amount
$30M
Amount sold
$15M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthias KleinzDirector
  • Mani MohindruExecutive Officer, Director
  • Jeanne CunicelliDirector
  • Greg DelgoffeDirector
Offering amount
$20M
Amount sold
$10M
First sale
Jun 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

GenentaGenenta Science is a clinical-stage biotechnology company developing Temferon, a hematopoietic stem cell-based gene therapy platform for treating cancer. The company is publicly traded on Nasdaq under the ticker GNTA.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
UPMCUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Enanta PharmaceuticalsEnanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).

Companies working in the same space as Novasenta.

Frequently asked questions

What does Novasenta do?
Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.
Who founded Novasenta?
Novasenta was founded by Greg M. Delgoffe, Robert Ferris, Dario A. A. Vignali in 2018.
Who are Novasenta's investors?
Novasenta's investors include UPMC Enterprises.
How much funding has Novasenta raised?
Novasenta has disclosed $25M raised across 2 rounds.
Where is Novasenta headquartered?
Novasenta is headquartered in Pittsburgh, US.